112 related articles for article (PubMed ID: 32386482)
21. Methylation site
Yang Z; Chen W; Zhu H; Zhang L; Zhou K; Tang H; Sun R; Huang Y; Xie H; Zheng S; Jia C
Future Oncol; 2022 Jun; 18(19):2401-2413. PubMed ID: 35502765
[No Abstract] [Full Text] [Related]
22. Methylation of PCDH19 predicts poor prognosis of hepatocellular carcinoma.
Zhang T; Guan G; Chen T; Jin J; Zhang L; Yao M; Qi X; Zou J; Chen J; Lu F; Chen X
Asia Pac J Clin Oncol; 2018 Oct; 14(5):e352-e358. PubMed ID: 29749051
[TBL] [Abstract][Full Text] [Related]
23. Hypomethylation of the cyclin D1 promoter in hepatitis B virus-associated hepatocellular carcinoma.
Liu HH; Fang Y; Wang JW; Yuan XD; Fan YC; Gao S; Han LY; Wang K
Medicine (Baltimore); 2020 May; 99(20):e20326. PubMed ID: 32443384
[TBL] [Abstract][Full Text] [Related]
24. Global Level of Plasma DNA Methylation is Associated with Overall Survival in Patients with Hepatocellular Carcinoma.
Yeh CC; Goyal A; Shen J; Wu HC; Strauss JA; Wang Q; Gurvich I; Safyan RA; Manji GA; Gamble MV; Siegel AB; Santella RM
Ann Surg Oncol; 2017 Nov; 24(12):3788-3795. PubMed ID: 28593503
[TBL] [Abstract][Full Text] [Related]
25. DNA methylation markers and serum α-fetoprotein level are prognostic factors in hepatocellular carcinoma.
Lin JC; Wu YC; Wu CC; Shih PY; Wang WY; Chien YC
Ann Hepatol; 2015; 14(4):494-504. PubMed ID: 26019036
[TBL] [Abstract][Full Text] [Related]
26. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma.
Xu RH; Wei W; Krawczyk M; Wang W; Luo H; Flagg K; Yi S; Shi W; Quan Q; Li K; Zheng L; Zhang H; Caughey BA; Zhao Q; Hou J; Zhang R; Xu Y; Cai H; Li G; Hou R; Zhong Z; Lin D; Fu X; Zhu J; Duan Y; Yu M; Ying B; Zhang W; Wang J; Zhang E; Zhang C; Li O; Guo R; Carter H; Zhu JK; Hao X; Zhang K
Nat Mater; 2017 Nov; 16(11):1155-1161. PubMed ID: 29035356
[TBL] [Abstract][Full Text] [Related]
27.
Anwar SL; Krech T; Hasemeier B; Schipper E; Schweitzer N; Vogel A; Kreipe H; Buurman R; Skawran B; Lehmann U
World J Gastroenterol; 2017 Mar; 23(9):1568-1575. PubMed ID: 28321157
[TBL] [Abstract][Full Text] [Related]
28. Methylation of IRAK3 is a novel prognostic marker in hepatocellular carcinoma.
Kuo CC; Shih YL; Su HY; Yan MD; Hsieh CB; Liu CY; Huang WT; Yu MH; Lin YW
World J Gastroenterol; 2015 Apr; 21(13):3960-9. PubMed ID: 25852282
[TBL] [Abstract][Full Text] [Related]
29. Methylation of tissue factor pathway inhibitor 2 as a prognostic biomarker for hepatocellular carcinoma after hepatectomy.
Sun FK; Sun Q; Fan YC; Gao S; Zhao J; Li F; Jia YB; Liu C; Wang LY; Li XY; Ji XF; Wang K
J Gastroenterol Hepatol; 2016 Feb; 31(2):484-92. PubMed ID: 26313014
[TBL] [Abstract][Full Text] [Related]
30. Cell-free methylation markers with diagnostic and prognostic potential in hepatocellular carcinoma.
Lu CY; Chen SY; Peng HL; Kan PY; Chang WC; Yen CJ
Oncotarget; 2017 Jan; 8(4):6406-6418. PubMed ID: 28031532
[TBL] [Abstract][Full Text] [Related]
31. Suppression of SAMSN1 Expression is Associated with the Malignant Phenotype of Hepatocellular Carcinoma.
Sueoka S; Kanda M; Sugimoto H; Shimizu D; Nomoto S; Oya H; Takami H; Ezaka K; Hashimoto R; Tanaka Y; Okamura Y; Yamada S; Fujii T; Nakayama G; Koike M; Fujiwara M; Kodera Y
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1453-60. PubMed ID: 25805236
[TBL] [Abstract][Full Text] [Related]
32. Hypermethylation of NF-κB-Activating Protein-Like (NKAPL) Promoter in Hepatocellular Carcinoma Suppresses Its Expression and Predicts a Poor Prognosis.
Ng PKS; Lau CPY; Lam EKY; Li SSK; Lui VWY; Yeo W; Ng YK; Lai PBS; Tsui SKW
Dig Dis Sci; 2018 Mar; 63(3):676-686. PubMed ID: 29353445
[TBL] [Abstract][Full Text] [Related]
33. Liquid biopsy by combining 5-hydroxymethylcytosine signatures of plasma cell-free DNA and protein biomarkers for diagnosis and prognosis of hepatocellular carcinoma.
Cai Z; Zhang J; He Y; Xia L; Dong X; Chen G; Zhou Y; Hu X; Zhong S; Wang Y; Chen H; Xie D; Liu X; Liu J
ESMO Open; 2021 Feb; 6(1):100021. PubMed ID: 33508734
[TBL] [Abstract][Full Text] [Related]
34. Downregulation of DENND2D by promoter hypermethylation is associated with early recurrence of hepatocellular carcinoma.
Kanda M; Nomoto S; Oya H; Takami H; Hibino S; Hishida M; Suenaga M; Yamada S; Inokawa Y; Nishikawa Y; Asai M; Fujii T; Sugimoto H; Kodera Y
Int J Oncol; 2014 Jan; 44(1):44-52. PubMed ID: 24189587
[TBL] [Abstract][Full Text] [Related]
35. Hypermethylation of ACP1, BMP4, and TSPYL5 in Hepatocellular Carcinoma and Their Potential Clinical Significance.
Qiu X; Hu B; Huang Y; Deng Y; Wang X; Zheng F
Dig Dis Sci; 2016 Jan; 61(1):149-57. PubMed ID: 26386860
[TBL] [Abstract][Full Text] [Related]
36. Disease progression from chronic hepatitis C to cirrhosis and hepatocellular carcinoma is associated with increasing DNA promoter methylation.
Zekri Ael-R; Nassar AA; El-Din El-Rouby MN; Shousha HI; Barakat AB; El-Desouky ED; Zayed NA; Ahmed OS; El-Din Youssef AS; Kaseb AO; Abd El-Aziz AO; Bahnassy AA
Asian Pac J Cancer Prev; 2014 Jan; 14(11):6721-6. PubMed ID: 24377595
[TBL] [Abstract][Full Text] [Related]
37. [Methylation pattern of DNA repair genes and microsatellite instability in hepatocelluar carcinoma].
Park JH; Cho SB; Lee WS; Park CH; Joo YE; Kim HS; Choi SK; Rew JS; Lee JH; Kim SJ
Korean J Gastroenterol; 2006 Nov; 48(5):327-36. PubMed ID: 17132921
[TBL] [Abstract][Full Text] [Related]
38. Decreased Expression of Fructose-1,6-bisphosphatase Associates with Glucose Metabolism and Tumor Progression in Hepatocellular Carcinoma.
Hirata H; Sugimachi K; Komatsu H; Ueda M; Masuda T; Uchi R; Sakimura S; Nambara S; Saito T; Shinden Y; Iguchi T; Eguchi H; Ito S; Terashima K; Sakamoto K; Hirakawa M; Honda H; Mimori K
Cancer Res; 2016 Jun; 76(11):3265-76. PubMed ID: 27197151
[TBL] [Abstract][Full Text] [Related]
39. Definition of the landscape of promoter DNA hypomethylation in liver cancer.
Stefanska B; Huang J; Bhattacharyya B; Suderman M; Hallett M; Han ZG; Szyf M
Cancer Res; 2011 Sep; 71(17):5891-903. PubMed ID: 21747116
[TBL] [Abstract][Full Text] [Related]
40. Predictive value of expression and promoter hypermethylation of XAF1 in hepatitis B virus-associated hepatocellular carcinoma treated with transplantation.
Zhang F; Wu LM; Zhou L; Chen QX; Xie HY; Feng XW; Zheng SS
Ann Surg Oncol; 2008 Dec; 15(12):3494-502. PubMed ID: 18830757
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
